Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 1
Submit an article Journal homepage
147
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes

Yang ZhangDepartment of Oncology, The Second Xiang-Ya Hospital, Central South University, Changsha, PR China; View further author information
,
Zhao ChengDepartment of Hematology, Institute of Molecular Hematology, The Second Xiang-Ya Hospital, Central South University, Changsha, PR ChinaView further author information
,
Wen-Zhe YanDepartment of Hematology, Institute of Molecular Hematology, The Second Xiang-Ya Hospital, Central South University, Changsha, PR ChinaView further author information
,
Su-Fang LiuDepartment of Hematology, Institute of Molecular Hematology, The Second Xiang-Ya Hospital, Central South University, Changsha, PR ChinaView further author information
,
Chun-Hong HuDepartment of Oncology, The Second Xiang-Ya Hospital, Central South University, Changsha, PR China; View further author information
&
Guang-Sen ZhangDepartment of Hematology, Institute of Molecular Hematology, The Second Xiang-Ya Hospital, Central South University, Changsha, PR ChinaCorrespondence[email protected]
View further author information
Pages 233-236 | Received 28 Dec 2016, Accepted 19 Apr 2017, Published online: 30 May 2017

References

  • Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–2384.
  • Schultheis B, Wang L, Clark RE, et al. BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis. Leukemia. 2003;17:2054–2055.
  • Demehri S, Paschka P, Schultheis B, et al. e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants? Leukemia. 2005;19:681–684.
  • Chen L, Wu Y, You Y, et al. A novel e8a2 BCR-ABL1 intronic fusion through insertion of a chromosome 22 BCR gene fragment into chromosome 9 in an atypical Philadelphia (Ph) chromosome chronic myeloid leukemia patient. Leuk Lymphoma. 2016;57:2930–2933.
  • Huet S, Dulucq S, Chauveau A, et al. Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts. Genes Chromosomes Cancer. 2015;54:595–605.
  • Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science. 1996;274:1001–1005.
  • Tchirkov A, Couderc JL, Perissel B, et al. Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript. Leukemia. 2006;20:167–168.
  • Qin YZ, Jiang B, Jiang Q, et al. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant. Acta Haematol. 2008;120:146–149.
  • Wang B, Moya N, Niessen S, et al. A hormone-dependent module regulating energy balance. Cell. 2011;145:596–606.
  • Ju H, Lee KA, Yang M, et al. TP53BP2 locus is associated with gastric cancer susceptibility. Int J Cancer. 2005;117:957–960.
  • Mak VC, Lee L, Siu MK, et al. Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation. Carcinogenesis. 2013;34:2170–2177.
  • Turnquist C, Wang Y, Severson DT, et al. STAT1-induced ASPP2 transcription identifies a link between neuroinflammation, cell polarity, and tumor suppression. Proc Natl Acad Sci USA. 2014;111:9834–9839.
  • Walker MM, Ellis SM, Auza MJ, et al. The intercellular adhesion molecule, cadherin-10, is a marker for human prostate luminal epithelial cells that is not expressed in prostate cancer. Mod Pathol. 2008;21:85–95.
  • Yu J, Wu WK, Li X, et al. Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut. 2015;64:636–645.
  • Li C, Gao Z, Li F, et al. Whole exome sequencing identifies frequent somatic mutations in cell–cell adhesion genes in Chinese patients with lung squamous cell carcinoma. Sci Rep. 2015;5:14237.
  • Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol. 2007;18(Suppl 6):vi42–vi46.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.